Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

313
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
313
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

410
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
410
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

From the arrhythmia to the substrate: the role of atrial cardiomyopathy in atrial fibrillation management.

Acta cardiologica·2026
Same author

Cardiovascular Involvement in Erdheim-Chester Disease Presenting as Pericardial Tamponade: A Case Report and Multimodality Imaging Review.

Journal of clinical medicine·2026
Same author

Acute and Chronic Myocarditis in Men and Women.

Current heart failure reports·2026
Same author

Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.

International journal of molecular sciences·2026
Same author

Conduction system pacing in heart failure: from guidelines to evidence and real-world practice.

Acta cardiologica·2026

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Advancing Heart Failure Care: Breakthroughs and Emerging Strategies.

Andrea Tedeschi1, Federico Barocelli2, Luigi Gerra1

  • 1Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy.

Journal of Clinical Medicine
|October 29, 2025
PubMed
Summary
This summary is machine-generated.

Recent heart failure therapies offer new hope, including novel drugs for diabetes and obesity, and interventions for tricuspid regurgitation. Advanced treatments aim to overcome organ shortages, shifting care towards precision medicine.

Keywords:
GLP-1 receptor agonistscell-free DNAdonation after circulatory deathfinerenoneheart failureprogresstotal artificial hearttricuspid regurgitationuptitration of GDMT

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

Area of Science:

  • Cardiology
  • Internal Medicine
  • Pharmacology

Background:

  • Heart failure (HF) is a complex syndrome with high mortality despite advances.
  • Therapeutic inertia and underdosing limit current HF management.
  • Understanding the HF continuum is crucial for effective treatment.

Purpose of the Study:

  • To review recent therapeutic advances in heart failure across the continuum of care.
  • To highlight established and emerging strategies for HF management.
  • To discuss innovations addressing organ shortages in advanced HF.

Main Methods:

  • Literature review of recent developments in heart failure therapy.
  • Focus on pharmacological and device-based interventions.
  • Analysis of emerging strategies for HF management.

Main Results:

  • Early initiation of foundational HF therapies reduces cardiovascular events but faces implementation challenges.
  • Novel agents like finerenone show cardiorenal benefits; GLP-1 agonists show promise in HFpEF/HFmrEF.
  • Transcatheter interventions for tricuspid regurgitation and innovations for organ donation/artificial hearts address advanced HF.

Conclusions:

  • Advances in HF care include precision-guided therapies and multidisciplinary approaches.
  • Novel pharmacological agents and interventions are expanding treatment options.
  • Addressing challenges in implementation and organ shortages is key for future HF management.